Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOLIFE2
2024-517018-14-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MaaT-033 and cemiplimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Disease control rate at week 12. Planned start Apr 2025; status: authorised.
02
Drugs
MaaT-033cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-517018-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517018-14-00.